TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06769542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental (micro teaching)
Description: The experimental group was taught using the micro-teaching method for 8 weeks. Psychomotor skills for drug administration were performed on models. Video recordings were taken while the students were performing the skills. These videos were evaluated by the instructor and the students and the students were given the opportunity to see their own mistakes. During 8 weeks, each student was given the opportunity to perform the applications and evaluate themselves. In addition, activities for drug applications were carried out with students within the scope of small group work. Micro teaching with 4 groups of 8 students was applied for 8 weeks.
Study: NCT06768749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin lotion
Description: 3 g lotion applied one hour before bedtime

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin lotion
Description: 3 g lotion applied one hour before bedtime

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo lotion
Description: 3 g of placebo lotion (scent-matched control) applied one hour before bedtime

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo lotion
Description: 3 g of placebo lotion (scent-matched control) applied one hour before bedtime
Study: NCT06768411

Intervention type: DRUG
Group type: OTHER
Intervention: PEG-rhGH
Description: 1= 0.2mg/kg/week Initial doses of PEG-rhGH 2=0.22mg/kg/week Initial doses of PEG-rhGH

Intervention type: DRUG
Group type: OTHER
Intervention: PEG-rhGH
Description: 1= 0.2mg/kg/week Initial doses of PEG-rhGH 2=0.22mg/kg/week Initial doses of PEG-rhGH

Intervention type: DRUG
Group type: OTHER
Intervention: GnRHa
Description: 1. pubertal children of short stature without GnRHa treatment~2. pubertal children of short stature with GnRHa treatment
Study: NCT06766435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-STAT TBI Test
Description: The Abbott i-STAT TBI test result is shared with the enrolled patient and treating clinicians.
Study: NCT06766890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeJoy+WeHop
Description: School-based CBT (WeJoy) comprises six weekly sessions on psychoeducation, cognitive restructuring, behavioural activation, emotional regulation, and self-monitoring. Exergaming on the interactive floor (WeHop) can gain a sense of autonomy, competence, and relatedness to help them regulate their emotions and maintain positive behaviours according to the Self-Determination Theory. Children participate in the interactive floor games by stepping on various targets and moving in response to the game's rules. Combining task division, cooperation, and taking turns constitutes the collaboration mechanism.
Study: NCT06765798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A : receive neural mobilization for radial nerve , mulligan mobilization with movement and conventional Therapy
Description: Group A :Neural Mobilization for radial nerve, Mulligan Mobilization with Movement and Conventional neural mobilization for radial nerve: The physiotherapist holds the patient's arm and wrist while the patient reclined on his side then depress the shoulder, extend the elbow and then internally rotated the patient's arm. The patient's wrist, thumb, and fingers were all flexed, and the patient's ulnar was brought to deviation. While the patient's position was maintained, and the arm was abducted and then contralateral cervical side bending Mulligan mobilization with movement manual lateral glide MWM with gripping: Patient: Supine with upper limb fully supported on a treatment table. Treated body part: Relaxed extension of the elbow, shoulder internal rotation, with pronation of the forearm. Hands loosely around the grip dynamometer handles. Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session, conventional ; Ultrasound therapy , stretching and strengthening for

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B receive neural mobilization for radial nerve and conventional
Description: Group B receive neural mobilization for radial nerve and conventional neural mobilization for radial nerve: The physiotherapist holds the patient's arm and wrist while the patient reclined on his side then depress the shoulder, extend the elbow and then internally rotated the patient's arm. The patient's wrist, thumb, and fingers were all flexed, and the patient's ulnar was brought to deviation. While the patient's position was maintained, and the arm was abducted and then contralateral cervical side bending conventional ; Ultrasound therapy , stretching and strengthening for wrist flexors and extensors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group C receive Mulligan mobilization with movement and conventional
Description: Group C receive Mulligan mobilization with movement and conventional~Mulligan mobilization with movement manual lateral glide MWM with gripping: Patient: Supine with upper limb fully supported on a treatment table. Treated body part: Relaxed extension of the elbow, shoulder internal rotation, with pronation of the forearm. Hands loosely around the grip dynamometer handles. Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session, conventional ; Ultrasound therapy , stretching and strengthening for wrist flexors and extensors
Study: NCT04980378

Intervention type: DEVICE
Intervention: Simplify Disc
Description: The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
Study: NCT05842447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 367 mg Pomanox group
Description: Treatment with 367 mg Pomanox®P30 during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 700 mg Pomanox group
Description: Treatment with 700 mg Pomanox®P30 during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Treatment with maltodextrin during 12 weeks
Study: NCT06765798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group D receive conventional
Description: Group D receive conventional :~Ultrasound therapy , stretching and strengthening for wrist flexors and extensors
Study: NCT06769984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTT11
Description: SCTT11 dose 1, dose 2, dose 3, dose 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose 1, dose 2, dose 3, dose 4
Study: NCT06769906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized automatic coaching message for glycemic management and depressive symptom
Description: For 12 weeks, the intervention group will apply continuous glucose monitoring system and receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires.
Study: NCT06767566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine (Ketalar)
Description: Loading Dose: 0.18 mg/kg/hr x 1 hour; Maintenance Dose 0.05 mg/kg/hr x 11 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine (Ketalar)
Description: Loading Dose: 0.18 mg/kg/hr x 1 hour; Maintenance Dose 0.05 mg/kg/hr x 11 hours
Study: NCT06766825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin 1.5 mg/day
Description: Receive 1.5 mg/day of plitidepsin intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo and Plitidepsin 1.5mg/day
Description: Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during two treatment periods and receive plitidepsin 1.5mg/day during the last two treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion.
Study: NCT06765616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab Injection combined with radiotherapy and chemotherapy
Description: Radiotherapy regimen: SCRT short-term radiotherapy of 5 × 5Gy Immunotherapy regimen: Adebrelimab Injection 1200 mg or 20 mg/kg, iv., followed by administration on the 1st day of each subsequent chemotherapy cycle.~Chemotherapy regimen: CAPOX regimen (chemotherapy cycle d1, to chemotherapy cycle d14):~Oxaliplatin 130 mg/m2 iv d1~Capecitabine 1000 mg/m2 po bid d1\~14~Repeat every 3 weeks for 6 cycles~After completing 6 cycles of chemotherapy, the patient underwent TME surgery 2-3 weeks later.
Study: NCT06765590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T, 260 mg/m2, paclitaxel for injection (albumin-bound)
Description: T, 260 mg/m2, paclitaxel for injection (albumin-bound)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R, 260 mg/m2, paclitaxel for injection (albumin bound).
Description: R, 260 mg/m2, paclitaxel for injection (albumin bound).
Study: NCT06766487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tongue resistance exercises
Description: The TRE program consisted of the following exercises:~Exercise 1: Tongue Protrusion and Retraction Against Resistance, Exercise 2: Anterior Tongue Protrusion and Retraction Against Resistance, Exercise 3: Middle Tongue Protrusion and Retraction Against Resistance, Exercise 4: Middle Tongue Elevation with Pharyngeal Sound Production, Exercise 5: Tongue Elevation and Posterior Sweeping, and Exercise 6: Saliva Swallowing with Lip Closure.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cheek bulging exercises
Description: Cheek bulging exercises involved a series of movements: Lip Closure: Participants began by closing their lips. Unilateral Cheek Bulging: They then bulged their right cheek, followed by relaxation and return to the initial position. This was repeated on the left side. Bilateral Cheek Bulging: Finally, participants bulged both cheeks simultaneously.
Study: NCT06769737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interventional group#1
Description: The intrathecal mixture of spinal anesthesia: 12 mg of isobaric Bupivacaine 0.5%, Bucaine®, (2.4 ml) + 20 mcg of Fentanyl, Martindale pharma Fentanyl®, 50mcg/ml (0.4ml) + 3 mcg of Dexmedetomidine HCL, Demexa®, 4mcg/ml (0.75 ml) total volume = 3.55 ml.~The Bromage score will be assessed by the anesthesiologist every 5 minutes after positioning the patient supine until the first incision. The Bromage score is a clinical scale used to determine motor block during regional anesthesia by evaluating lower limb movement: Grade 0: Full movement of hips, knees, and ankles (no block). Grade 1: Unable to lift the leg but can move knees and ankles (partial block). Grade 2: Unable to bend the knee but can move ankles (near-complete block). Grade 3: No movement in hips, knees, or ankles (complete block). Dermatomal coverage will be assessed simultaneously till it reaches the L1-L2 level. Also, The Ramsay Sedation Scale (RSS) will be used to evaluate the sedation depth, if any.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interventional group#2
Description: The intrathecal mixture of spinal anesthesia: 12 mg of isobaric Bupivacaine 0.5%, Bucaine®, (2.4 ml) + 20 mcg of Fentanyl, Martindale pharma Fentanyl®, 50mcg/ml (0.4ml) total volume = 2.8 ml.~The intravascular mixture consists of 0.5 mcg/kg of Dexmedetomidine HCL, Demexa®, and a maximum of 30 mcg diluted to 4 mcg/ml. According to body weight, the total volume is 7.5 ml or less and given using a syringe pump over 30 minutes. The anesthesiologist will start the infusion once the patient is positioned supine post-spinal anesthesia and has stable hemodynamics. The Bromage score will be assessed by the anesthesiologist every 5 minutes after positioning the patient supine until the first incision reaches grade 3: No movement in hips, knees, or ankles (complete block). The anesthesiologist will assess dermatomal coverage until it reaches the L1-L2 and calculate the Ramsay Sedation Scale (RSS) of the depth of sedation aiming for level 2: Patient is cooperative, oriented, and calm
Study: NCT06766240

Intervention type: DEVICE
Intervention: MRI on lumbosacral spine
Description: MRI imaging on lumbosacral spine using Philips Achieva1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea1.5T MRI device (Siemens Healthineers, Germany). the sequences used are Axial T2W; Sagittal T1W, T2W, Sagittal STIR, Coronal STIR and post gadolinium if needed.
Study: NCT06763757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy Program
Description: The Art Therapy Program consists of 12 weekly group sessions, each lasting 90 minutes, designed to improve emotional well-being and quality of life in solitary older adults. Participants engage in structured activities that include creating art (e.g., drawing and painting), observing and interpreting art pieces, and reflective discussions to explore personal emotions and experiences. The sessions are led by trained facilitators under the supervision of licensed occupational therapists. This intervention follows a thematic progression: initial sessions focus on building trust and self-expression, mid-sessions deepen emotional awareness, and final sessions culminate in a creative project reflecting the participant's personal growth. Unlike other interventions, this program is tailored specifically for older adults living alone, addressing their unique challenges of isolation and reduced social interaction.
Study: NCT06763172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Description: Caffeine (200mg) will be administered per os 20 minutes prior to the PET/fMRI data acquisition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose tablet will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
Study: NCT06765538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video consultation
Description: Preanaesthetic videoconsultation
Study: NCT06765018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Brush (Orabrush)
Description: Patients in this group uses the Tongue Brush (Orabrush) 2 times a day for a duration for 3-5 days until the follow-up-screening takes place.
Study: NCT06767098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: theraputic exercises for neck muscles and smartphone holder
Description: strech and strength exercises for neck muscles. and using smartphone holder daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: theraputic exercises for neck muscles
Description: strech and strength exercises for neck muscles.
Study: NCT06520982

Intervention type: DRUG
Group type: OTHER
Intervention: Norepinephrine
Description: Infused intra-arterially in a dose-response fashion

Intervention type: DRUG
Group type: OTHER
Intervention: Isoproterenol
Description: Infused intra-arterially in a dose-response fashion

Intervention type: DRUG
Group type: OTHER
Intervention: Acetylcholine
Description: Infused intra-arterially in a dose-response fashion
Study: NCT06769126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saruparib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation Therapy
Description: Undergo thoracic radiation
Study: NCT06520982

Intervention type: DRUG
Group type: OTHER
Intervention: Nitroprusside
Description: Infused intra-arterially in a dose-response fashion

Intervention type: DRUG
Group type: OTHER
Intervention: Estrogen
Description: Infused intra-arterially
Study: NCT05622305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-Day Cognitive Behavioural Therapy-Based Workshop
Description: The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
Study: NCT06769126

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation Therapy
Description: Undergo thoracic radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation Therapy
Description: Undergo thoracic radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation Therapy
Description: Undergo thoracic radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation Therapy
Description: Undergo thoracic radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation Therapy
Description: Undergo thoracic radiation
Study: NCT06768658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951
Description: TAK-951 subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951
Description: TAK-951 subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951 Placebo
Description: TAK-951 placebo-matching subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951 Placebo
Description: TAK-951 placebo-matching subcutaneous injection.
Study: NCT06768996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Synchronous Rhythm Production
Description: The treatment group will take part in a dyad-based musical rhythm production activity facilitated by a trained musician. This activity will involve two rhythm conditions. The first condition requires tapping along to one pre-recorded audio track composed of an ensemble of Brazilian percussion instruments. The second condition requires tapping along with prerecorded audio tracks of rhythms progressively increasing in difficulty. Participants who indicate proficiency in learning to tap along in both conditions will be able to progress to more complex rhythms. All tapping data will be gathered through a Roland digital hand percussion controller.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Solo Rhythm Production
Description: Participants randomized to the control condition will complete the same rhythm conditions to the same recorded audio tracks described in the experimental condition. However, they will not interchange their tapping with their caregiver. They will participate in the rhythm task as a solo producer.
Study: NCT06768099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linear Cognitive Aid
Description: Key features of this tool include:~* Minimal input: Teams input the patient's age and clinical scenario (e.g. arrest, childbirth, or trauma).~* Linear logic: Based on initial simple input, the tool provides straightforward guidance without requiring multiple Y/N input or advanced decision-making.~* Guidance based on individual characteristics: The tool tailors AHA guidance for the specific emergency scenario to the individual patient's size (estimated by age), emphasizing key interventions for the individual scenario and giving appropriate size-based guidance regarding choice of equipment, medication dosage, and resuscitation technique (e.g., chest compression depth).~* Time-based and on-demand guidance: Based on the time elapsed from the start of the resuscitation, the app will provide audio guidance regarding the next key steps.
Study: NCT06768385

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Description: : It was performed under USG guidance using 30 ml of 0.25% bupivacaine with an 80 mm insulated peripheral block needle. Local anaesthetic was applied between the upper fascia of the transversus abdominus muscle and the fascia of the internal oblique muscle at the midpoint of the distance between the costal margin and the iliac crest in the midaxillary line under USG imaging guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracoabdominal nerve blockage with perichondrial approach (TAPA) block
Description: Under USG guidance, 20 ml of 0.25% bupivacaine was administered between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue at the level of the 9th and 10th ribs (arcus costarum) in the midclavicular line with an 80 mm insulated peripheral block needle. Then, 10 ml of 0.25% bupivacaine was injected into the upper fascia of the costochondral tissue and the lower fascia of the external oblique muscle. The block was performed by following the needle path in the ultrasound image.